160P - Pretreatment serum albumin level is an independent prognostic biomarker in malignant pleural mesothelioma

Date 17 April 2015
Event ELCC 2015
Session Poster lunch
Topics Mesothelioma
Translational Research
Presenter Thomas Klikovits
Citation Annals of Oncology (2015) 26 (suppl_1): 48-50. 10.1093/annonc/mdv052
Authors T. Klikovits1, P. Stockhammer2, Y. Dong2, M. Jakopovic3, L. Brcic4, B. Dome1, B. Hegedus1, M. Samarzija3, W. Klepetko1, M.A. Hoda1
  • 1Division Of Thoracic Surgery, Medizinische Universitaet Wien (Medical University of Vienna), 1090 - Vienna/AT
  • 2Division Of Thoracic Surgery, Medizinische Universitaet Wien (Medical University of Vienna), Vienna/AT
  • 3Department Of Pulmonology, KBC Zagreb--Jordanovac Clinic for Lung Diseases, Zagreb/HR
  • 4Department Of Pathology, KBC Zagreb--Jordanovac Clinic for Lung Diseases, Zagreb/HR

Abstract

Aim/Background

Malignant Pleural Mesothelioma (MPM) is an aggressive thoracic tumor with dismal outcome. Therapeutic decision is challenging and prognostic biomarkers are urgently needed. The aim of this investigation was to evaluate the prognostic impact of pre-interventional serum albumin (SA) levels in MPM patients.

Methods

A retrospective review of a prospective database of 227 patients with histopathologically verified MPM and complete clinical follow-up diagnosed between 1994 and 2014 at two different institutions was conducted. All SA levels were measured during routine work-up before any diagnostic/therapeutic intervention. Cut-off for SA was defined at the clinically significant level of 35 mg/dl. The association between SA levels and survival was analyzed using Cox models adjusted for clinical and pathological factors.

Results

180 males and 47 females with a mean age of 64 ± 11.3 years at the time of diagnosis were included. Main histological subtype was epitheloid (169 patients; 74.4%). Median overall survival for all patients was 12.4 months (95% confidence interval [CI] 9.8–14.9 months). Patients with normal SA (≥ 35 mg/dl) at the time of diagnosis had a significant better median overall survival (14.3 months, 95%CI 11.3–17.4) compared to patients with low SA levels (7.6 months, 95%CI 5–10.1, hazard ratio [HR] 1.56, p = 0.003). In the multivariate survival analysis SA (p = 0.02), age (≥ 65 years, p = 0.001) and histology (epitheloid vs. non-epitheloid, p = 0.03) were found to be independent prognostic factors.

Conclusions

Pre-interventional SA level is an independent prognostic factor in MPM.

Disclosure

All authors have declared no conflicts of interest.